Biophytis (EPA:ALBPS) | WebDisclosure

REGULATED PRESS RELEASE

published on 03/22/2024 at 07:00, 2 years 6 months ago

Biophytis a présenté son protocole de phase 3 dans le traitement de la sarcopénie
Biophy's présente son protocole de phase 3 pour traiter la sarcopénie lors de l'ICFSR. L'étude SARA-31 évaluera l'efficacité de RuvembriTM. Biophytis recherche des partenaires pour le développement

Biophytis RuvembriTM Sarcopénie Biophy's Protocole De Phase 3
REGULATED PRESS RELEASE

published on 03/22/2024 at 07:00, 2 years 6 months ago

Biophytis presented its phase 3 protocol in the treatment of sarcopenia
Biophytis presents phase 3 protocol for sarcopenia treatment at ICFSR conference, showcasing the potential of RuvembriTM. CEO Stanislas Veillet seeks partners for drug development and financing

Biophytis RuvembriTM Clinical-stage Biotechnology Phase 3 Protocol Sarcopenia Treatment
BRIEF

published on 03/18/2024 at 07:05, 2 years 6 months ago

Biophytis annonce sa prochaine Assemblée Générale Mixte pour le 02 avril 2024

Biophytis Assemblée Générale Mixte Société Biotechnologique Vote Des Actionnaires Médicaments Vieillissement
BRIEF

published on 03/18/2024 at 07:05, 2 years 6 months ago

Biophytis Announces Combined General Meeting for April 2024

Biophytis RuvembriTM Clinical-stage Biotechnology Combined General Meeting Age-related Diseases
REGULATED PRESS RELEASE

published on 03/18/2024 at 07:00, 2 years 6 months ago

Assemblée générale mixte du 02 avril 2024
Assemblée générale mixte de Biophytis SA prévue le 02 avril 2024 à Paris. Actionnaires invités à voter en amont. Informations sur le site internet de la Société

Assemblée Générale Mixte Biophytis SA Vote Actionnaires Développement Médicaments Maladies Liées Au Vieillissement
REGULATED PRESS RELEASE

published on 03/18/2024 at 07:00, 2 years 6 months ago

Combined General Meeting of April 2, 2024
Biophytis SA will hold its Combined General Meeting (CGM) on April 2, 2024 at Sorbonne Université, Paris. Shareholders can vote in advance. The company specializes in developing therapies for age-related diseases

Therapeutics Combined General Meeting Biophytis SA Age-related Diseases CGM
BRIEF

published on 03/15/2024 at 23:05, 2 years 6 months ago

Biophytis met en œuvre le regroupement de ses actions pour réduire la volatilité

Marché Financier Biophytis Biotechnologie Regroupement D'actions Volatilité Du Titre
BRIEF

published on 03/15/2024 at 23:05, 2 years 6 months ago

Biophytis Announces Reverse Stock Split on Euronext Growth

Biophytis Biotechnology Shareholder Value Reverse Stock Split Euronext Growth
REGULATED PRESS RELEASE

published on 03/15/2024 at 23:00, 2 years 6 months ago

Biophytis annonce le lancement du regroupement des actions composant son capital social
Biophytis annonce le regroupement des actions de son capital social pour stabiliser l'action et favoriser son développement. Détails du regroupement et calendrier prévus

Euronext Growth Paris Actionnaires Biophytis Regroupement Des Actions Stabilisation
REGULATED PRESS RELEASE

published on 03/15/2024 at 23:00, 2 years 6 months ago

Biophytis announces the implementation of a reverse stock split of its ordinary shares traded on Euronext Growth
Biophytis implements a reverse stock split for its ordinary shares on Euronext Growth Paris and Nasdaq CM to stabilize share price. Details of the operation and key dates provided

Biophytis Reverse Stock Split Euronext Growth Nasdaq CM Share Price Stabilization

Published on 09/23/2026 at 22:00, 1 hour 57 minutes ago

Petrolympic Adopts Semi-Annual Financial Reporting
Published on 09/23/2026 at 18:25, 5 hours 32 minutes ago

Boba Mint Holdings Ltd. Reports Strong Early Subscription Adoption Following Soft Launch of Amino Pro
Published on 09/23/2026 at 15:42, 8 hours 15 minutes ago

Global Atomic Announces C$50 Million Public Offering of Units
Published on 09/23/2026 at 14:31, 9 hours 26 minutes ago

First Breach Completes First Untethered Flight of Proprietary Drone Prototype, Advancing American-Made Unmanned Systems Program
Published on 09/23/2026 at 14:30, 9 hours 27 minutes ago

Phase II Clinical Trial of NV-387 as a Treatment for Monkeypox (MPox) Has Begun in DRC, Announces NanoViricides

View all ACCESSWIRE

Published on 09/23/2026 at 23:00, 57 minutes ago

Correction d’un communiqué du 23.09.2026 18:00 CET/CEST - MHM CORPORATE ANNONCE LE SUCCÈS DE SON AUGMENTATION DE CAPITAL AVEC MAINTIEN DU DROIT PREFERENTIEL DE SOUSCRIPTION AINSI QU’UN REMBOURSEMENT PARTIEL D’OBLIGATIONS REMBOURSABLES EN ACTIONS
Published on 09/23/2026 at 23:00, 57 minutes ago

Correction of a release from 23.09.2026 18:00 CET/CEST - MHM CORPORATE ANNOUNCES THE SUCCESS OF ITS CAPITAL INCREASE WITH PREFERENTIAL SUBSCRIPTION RIGHTS AND THE PARTIAL EARLY REDEMPTION OF BONDS REDEEMABLE IN SHARES
Published on 09/23/2026 at 19:51, 4 hours 5 minutes ago

LIGHTON: LightOn renouvelle son financement obligataire auprès des mêmes partenaires financiers pour un montant nominal maximum de 4 millions d’euros, et étend ainsi son horizon de trésorerie
Published on 09/23/2026 at 19:51, 4 hours 5 minutes ago

LIGHTON: LightOn renews its bond financing with the same financial partners for a maximum nominal amount of €4 million, and thus extends its cash flow horizon
Published on 09/23/2026 at 19:30, 4 hours 27 minutes ago

EUROPLASMA: Valdunes Industries et Saarstahl Ascoval s’associent pour développer une nouvelle génération de « roues vertes »

View all EQS

Published on 09/23/2026 at 19:46, 4 hours 10 minutes ago

SFPI GROUP: half year 2026 results
Published on 09/23/2026 at 19:46, 4 hours 10 minutes ago

SFPI GROUP: publication des résultats semestriels 2026
Published on 09/23/2026 at 19:14, 4 hours 42 minutes ago

Robust performance from Investments and continued execution of the strategy
Published on 09/23/2026 at 19:14, 4 hours 42 minutes ago

Performance robuste des Investissements, poursuite du déploiement de la stratégie
Published on 09/23/2026 at 18:00, 5 hours 57 minutes ago

CIS : H1 2026 results.

View all LES ECHOS COMFI WIRE

News